January 12, 2005 -- In a statement, Mylan Labs Chief Executive Robert Coury said his company’s merger with King Pharmaceuticals was highly unlikely under the current terms. In the original deal, Mylan had written in an escape clause without financial penalty if King had to make any financial restatements. That’s exactly what happened, but we don’t think it’s the real reason. We look at the possibilities...
